X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (3018) 3018
Journal Article (2831) 2831
Conference Proceeding (137) 137
Publication (137) 137
Dissertation (10) 10
Book / eBook (6) 6
Book Chapter (6) 6
Paper (6) 6
Report (5) 5
Technical Report (2) 2
Compact Disc (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
physics (1021) 1021
chemistry (910) 910
metallurgy (899) 899
electricity (872) 872
human necessities (731) 731
performing operations (689) 689
transporting (689) 689
humans (686) 686
hygiene (592) 592
medical or veterinary science (592) 592
general tagging of cross-sectional technologies spanning over several sections of the ipc (591) 591
general tagging of new technological developments (591) 591
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (591) 591
index medicus (558) 558
male (541) 541
organic chemistry (521) 521
female (491) 491
preparations for medical, dental, or toilet purposes (468) 468
heterocyclic compounds (467) 467
specific therapeutic activity of chemical compounds ormedicinal preparations (425) 425
basic electric elements (423) 423
technical subjects covered by former uspc (402) 402
middle aged (349) 349
technical subjects covered by former us classification (349) 349
electric communication technique (343) 343
mechanical engineering (334) 334
heating (333) 333
blasting (332) 332
lighting (332) 332
weapons (332) 332
aged (315) 315
counting (309) 309
calculating (307) 307
computing (307) 307
adult (270) 270
physical or chemical processes or apparatus in general (259) 259
electric digital data processing (257) 257
pictorial communication, e.g. television (240) 240
animals (231) 231
apparatus therefor (223) 223
separation (214) 214
optics (206) 206
general methods of organic chemistry (194) 194
technologies or applications for mitigation or adaptation againstclimate change (181) 181
measuring (175) 175
testing (175) 175
electric solid state devices not otherwise provided for (160) 160
semiconductor devices (160) 160
engineering elements and units (155) 155
general measures for producing and maintaining effectivefunctioning of machines or installations (155) 155
surgery (155) 155
thermal insulation in general (155) 155
acyclic or carbocyclic compounds (146) 146
education (142) 142
advertising (141) 141
cryptography (141) 141
display (141) 141
seals (141) 141
aged, 80 and over (132) 132
analysis (126) 126
photography (125) 125
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (124) 124
cinematography (122) 122
electrography (122) 122
holography (122) 122
arrangements or circuits for control of indicating devicesusing static means to present variable information (115) 115
electric techniques not otherwise provided for (114) 114
oncology (111) 111
biochemistry & molecular biology (110) 110
japan (108) 108
fixed constructions (107) 107
casings or constructional details of electric apparatus (99) 99
manufacture of assemblages of electrical components (99) 99
printed circuits (99) 99
diagnosis (98) 98
mice (98) 98
shafts (96) 96
cancer (94) 94
prognosis (94) 94
treatment outcome (94) 94
cardiac & cardiovascular systems (92) 92
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (92) 92
frequency-changing (92) 92
non-linear optics (92) 92
optical analogue/digital converters (92) 92
optical logic elements (92) 92
techniques or procedures for the operation thereof (92) 92
microbiology (91) 91
dyes (90) 90
generation (90) 90
adhesives (89) 89
miscellaneous applications of materials (89) 89
miscellaneous compositions (89) 89
natural resins (89) 89
paints (89) 89
polishes (89) 89
research (89) 89
compositions based thereon (88) 88
organic macromolecular compounds (88) 88
their preparation or chemical working-up (88) 88
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5590) 5590
French (534) 534
German (435) 435
Japanese (347) 347
Chinese (221) 221
Korean (55) 55
Spanish (35) 35
Portuguese (30) 30
Norwegian (24) 24
Polish (18) 18
Danish (16) 16
Finnish (9) 9
Greek (9) 9
Slovenian (9) 9
Russian (7) 7
Ukrainian (6) 6
Swedish (3) 3
Croatian (2) 2
Czech (2) 2
Turkish (2) 2
Arabic (1) 1
Hungarian (1) 1
Indonesian (1) 1
Italian (1) 1
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Yamagami, Keitaro and Kurogi, Ryota and Kurogi, Ai and Nishimura, Hiroyuki and Nishimura, Shinjitsu and Nishimura, Yasuaki and Nishimura, Kunihiro and Nishimura, Ataru and Onozuka, Daisuke and Ren, Nice and Kada, Akiko and Arimura, Koichi and Ido, Keisuke and Mizoguchi, Masahiro and Sakamoto, Seisaburo and Sakamoto, Tetsuya and Kayama, Takamasa and Suzuki, Nozomi and Suzuki, Michiyasu and Suzuki, Sachio and Suzuki, Hidenori and Suzuki, Ichiro and Suzuki, Susumu and Arai, Yoshinori and Arai, Hajime and Arai, Motohiro and Hagihara, Akihito and Iihara, Koji and Takigami, Masayoshi and Kamiyama, Kenji and Houkin, Kiyohiro and Nishi, Shougo and Yoshimoto, Tetsuyuki and Yoshimoto, Junpei and Kaneko, Sadao and Oka, Hirofumi and Oka, Koji and Ooyama, Hiroshi and Kamada, Kyousuke and Makino, Kenichi and Tokumitsu, Naoki and Sako, Kazuhiro and Izumi, Naoto and Nitta, Hisashi and Nitta, Kazumi and Ootaki, Masahumi and Isobe, Masanori and Nishiya, Mikio and Yamazaki, Takaaki and Mabuchi, Syouji and Mabuchi, Eiichiro and Ogasawara, Kuniaki and Kubo, Naohiko and Shimizu, Yukihiko and Saito, Hitoshi and Saito, Keiichi and Yamanome, Tatumi and Yoshino, Kimihiro and Yoshino, Atsuo and Fujitsuka, Mitsuyuki and Takami, Masaaki and Ohtaka, Hirotoshi and Hirano, Teruyuki and Shiokawa, Yosiaki and Okada, Takaharu and Kohno, Michihiro and Haraoka, Jou and Kawamura, Noriyoshi and Kawamura, Tadao and Isoshima, Akira and Yasue, Masaharu and Takayoshi Kobayashi, Mitsuhiko Hokari and Kawai, Kensuke and Maehara, Taketoshi and Noguchi, Makoto and Hoshino, Haruhiko and Hiyama, Hirofumi and Yoshida, Kensaku and Yoshida, Kazunari and Utsugi, Osamu and Takeda, Yasuaki and Takeda, Yuu and Tamaki, Kouichi and Karasudani, Hirohide and Urabe, Takao and Kobayashi, Nozomu and Kobayashi, Shiro and Nakamura, Yusaku and Nakamura, Kazuhito and Nakamura, Michio and Nakamura, Yoshinari and Koguchi, Yorio and Ono, Junichi and Suda, Sumio and Hadeishi, Hiromu and Fukutake, Toshio and Wakui, Kenji and Tanno, Hirokazu and Ishige, Naoki and Ohasi, Takashi and ... and J-ASPECT Study Collaborators
World Neurosurgery, ISSN 1878-8750, 10/2019, Volume 130, pp. e26 - e46
The epidemiology of patients with traumatic brain injury (TBI) has changed dramatically over recent decades as a result of rapid advances in aging societies.... 
Aging | Hospital mortality | Prognosis | Traumatic brain injury | Subdural hematoma | SURGERY | CARE | CLINICAL NEUROLOGY | IMPACT | CLINICAL-VARIABLES | HOSPITAL VOLUME | GENDER | COMA
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
by Aharonian, Felix and Akamatsu, Hiroki and Akimoto, Fumie and Allen, Steven W and Anabuki, Naohisa and Angelini, Lorella and Arnaud, Keith and Audard, Marc and Awaki, Hisamitsu and Axelsson, Magnus and Bamba, Aya and Bautz, Marshall and Blandford, Roger and Brenneman, Laura and Brown, Gregory V and Bulbul, Esra and Cackett, Edward and Chernyakova, Maria and Chiao, Meng and Coppi, Paolo and Costantini, Elisa and De Plaa, Jelle and Den Herder, Jan-Willem and Done, Chris and Dotani, Tadayasu and Ebisawa, Ken and Eckart, Megan and Enoto, Teruaki and Ezoe, Yuichiro and Fabian, Andrew C and Ferrigno, Carlo and Foster, Adam and Fujimoto, Ryuichi and Fukazawa, Yasushi and Furuzawa, Akihiro and Galeazzi, Massimiliano and Gallo, Luigi and Gandhi, Poshak and Giustini, Margherita and Goldwurm, Andrea and Gu, Liyi and Guainazzi, Matteo and Haba, Yoshito and Hagino, Kouichi and Hamaguchi, Kenji and Harrus, Ilana and Hatsukade, Isamu and Hayashi, Katsuhiro and Hayashi, Takayuki and Hayashida, Kiyoshi and Hiraga, Junko and Hornschemeier, Ann and Hoshino, Akio and Hughes, John and Iizuka, Ryo and Inoue, Hajime and Inoue, Yoshiyuki and Ishibashi, Kazunori and Ishida, Manabu and Ishikawa, Kumi and Ishisaki, Yoshitaka and Itoh, Masayuki and Iyomoto, Naoko and Kaastra, Jelle and Kallman, Timothy and Kamae, Tuneyoshi and Kara, Erin and Kataoka, Jun and Katsuda, Satoru and Katsuta, Junichiro and Kawaharada, Madoka and Kawai, Nobuyuki and Kelley, Richard and Khangulyan, Dmitry and Kilbourne, Caroline and King, Ashley and Kitaguchi, Takao and Kitamoto, Shunji and Kitayama, Tetsu and Kohmura, Takayoshi and Kokubun, Motohide and Koyama, Shu and Koyama, Katsuji and Kretschmar, Peter and Krimm, Hans and Kubota, Aya and Kunieda, Hideyo and Laurent, Philippe and Lebrun, François and Lee, Shiu-Hang and Leutenegger, Maurice and Limousin, Olivier and Loewenstein, Michael and Long, Knox S and Lumb, David and Madejski, Grzegorz and Maeda, Yoshitomo and Maier, Daniel and Makishima, Kazuo and Markevitch, Maxim and ... and Hitomi Collaboration and SLAC National Accelerator Lab., Menlo Park, CA (United States)
Nature, ISSN 0028-0836, 07/2016, Volume 535, Issue 7610, pp. 117 - 121
Clusters of galaxies are the most massive gravitationally bound objects in the Universe and are still forming. They are thus important probes(1) of... 
NGC 1275 | GALAXY CLUSTERS | TURBULENT VELOCITY | MULTIDISCIPLINARY SCIENCES | LINE | GAS | NGC-1275 | CONSTRAINTS | X-RAY SPECTROSCOPY | XMM-NEWTON | FEEDBACK | Clusters | Observations | Stars | Cosmology | Astrophysics | Velocity | Stars & galaxies | ASTRONOMY AND ASTROPHYSICS | GRQC | ASTRO
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
by Takahashi, Tadayuki and Kokubun, Motohide and Mitsuda, Kazuhisa and Kelley, Richard and Ohashi, Takaya and Aharonian, Felix and Akamatsu, Hiroki and Akimoto, Fumie and Allen, Steve and Anabuki, Naohisa and Angelini, Lorella and Arnaud, Keith and Asai, Makoto and Audard, Marc and Awaki, Hisamitsu and Axelsson, Magnus and Azzarello, Philipp and Baluta, Chris and Bamba, Aya and Bando, Nobutaka and Bautz, Marshall and Bialas, Thomas and Blandford, Roger and Boyce, Kevin and Brenneman, Laura and Brown, Greg and Bulbul, Esra and Cackett, Edward and Canavan, Edgar and Chernyakova, Maria and Chiao, Meng and Coppi, Paolo and Costantini, Elisa and De Plaa, Jelle and Den Herder, Jan-Willem and DiPirro, Michael and Done, Chris and Dotani, Tadayasu and Doty, John and Ebisawa, Ken and Eckart, Megan and Enoto, Teruaki and Ezoe, Yuichiro and Fabian, Andrew and Ferrigno, Carlo and Foster, Adam and Fujimoto, Ryuichi and Fukazawa, Yasushi and Furuzawa, Akihiro and Galeazzi, Massimiliano and Gallo, Luigi and Gandhi, Poshak and Gilmore, Kirk and Giustini, Margherita and Goldwurm, Andrea and Gu, Liyi and Guainazzi, Matteo and Haas, Daniel and Haba, Yoshito and Hagino, Kouichi and Hamaguchi, Kenji and Harayama, Atsushi and Harrus, Ilana and Hatsukade, Isamu and Hayashi, Takayuki and Hayashi, Katsuhiro and Hayashida, Kiyoshi and Hiraga, Junko and Hirose, Kazuyuki and Hornschemeier, Ann and Hoshino, Akio and Hughes, John and Ichinohe, Yuto and Iizuka, Ryo and Inoue, Yoshiyuki and Inoue, Hajime and Ishibashi, Kazunori and Ishida, Manabu and Ishikawa, Kumi and Ishimura, Kosei and Ishisaki, Yoshitaka and Itoh, Masayuki and Iwata, Naoko and Iyomoto, Naoko and Jewell, Chris and Kaastra, Jelle and Kallman, Timothy and Kamae, Tuneyoshi and Kara, Erin and Kataoka, Jun and Katsuda, Satoru and Katsuta, Junichiro and Kawaharada, Madoka and Kawai, Nobuyuki and Kawano, Taro and Kawasaki, Shigeo and Khangulyan, Dmitry and Kilbourne, Caroline and Kimball, Mark and King, Ashley and ...
Proceedings of SPIE - The International Society for Optical Engineering, ISSN 0277-786X, 2016, Volume 9905
Conference Proceeding
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article